Wet AMD: Current treatments and emerging therapies: Experts discuss durability of action and atrophy inhibitor among primary treatment goals.

The article discusses a virtual meeting on treatment strategies for wet age-related macular degeneration (AMD) in 2021. Topics covered include the efficacy of the anti-vascuular endothelial growth factor (VEGF) drugs bevacizumab and ranibizumab, the decrease of risk by antisepsis of the eye, a nonexudative neovascular form of AMD in a lesion manifestation, and the treat and extend procedure. Also noted is the emerging therapy faricimab.